Immunic (IMUX) Stock Price, Quote, News & History | Benzinga

Immunic Inc (IMUX) Stock Price, Quote, News & History

IMUXNASDAQ

Trade with Public

Trade with Public

$15.40

-0.90-5.52%

At close: Aug 28, 5:00 PM EST

$16.23

0.835.42%

After Hours: Aug 28, 7:46 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$16.21

Close

$15.40

Volume / Avg.

357.93K / 192.91K

Day Range

$15.00 - $16.30

52 Wk Range

5.06 - 17.43

Market Cap

$221.51M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

9.9%

Days to Cover

7.01

Recent Immunic, Inc. News

EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO

Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic's Phase 3 trials in 2026.

Anusuya Lahiri

Amazon To Rally More Than 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings

Avi Kapoor

Immunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy

Immunic appoints Michael Panzara as CMO, granting inducement equity award as he takes charge of clinical and regulatory strategy.

Vandana Singh

Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says

Stifel initiates coverage on Immunic (IMUX) with a Buy rating. Analysts see potential for VidoCa to disrupt the MS market via better safety.

Vandana Singh

This Parsons Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings and analysts' views on PSN.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-87.72M

Investing Cash Flow (TTM)

-329.00K

Financing Cash Flow (TTM)

188.82M

Free Cash Flow (TTM)

-88.05M

Capital Expenditure (TTM)

-329.00K

Net Change in Cash (TTM)

100.77M

Analyst Trends and Forecast

2

Mar

2

Apr

1

May

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$55.59M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.74

Earnings Yield % (TTM)

-21.78%

Earnings Yield % (FWD)

-23.68%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$9.35

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$155.10M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$16.21

Close

$15.40

Volume / Avg.

357.93K / 192.91K

Day Range

$15.00 - $16.30

52 Wk Range

5.06 - 17.43

Market Cap

$221.51M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

9.9%

Days to Cover

7.01

About

Sector

Health Care

Industry

Biotechnology

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Immunic (IMUX) stock?

A

You can purchase shares of Immunic (NASDAQ:IMUX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Immunic (IMUX) competitors?

A

Other companies in Immunic’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Immunic (IMUX) stock?

A

Immunic has a consensus price target of $15.77.

Q

What is the current price for Immunic (IMUX)?

A

The stock price for Immunic (NASDAQ: IMUX) is $16.2347 last updated August 28, 2026 at 7:46 AM EDT.

Q

Does Immunic (IMUX) pay a dividend?

A

There are no upcoming dividends for Immunic.

Q

When is Immunic (NASDAQ:IMUX) reporting earnings?

A

Immunic does not have any upcoming earnings scheduled.

Q

Is Immunic (IMUX) going to split?

A

There is no upcoming split for Immunic.

Q

What sector and industry does Immunic (IMUX) operate in?

A

Immunic is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.